Vericel Management
Management criteria checks 3/4
Vericel's CEO is Nick Colangelo, appointed in Mar 2013, has a tenure of 13.42 years. total yearly compensation is $11.16M, comprised of 7.7% salary and 92.3% bonuses, including company stock and options. directly owns 0.61% of the company’s shares, worth $13.94M. The average tenure of the management team and the board of directors is 4.9 years and 13.4 years respectively.
Key information
Nick Colangelo
Chief executive officer
US$11.2m
Total compensation
| CEO salary percentage | 7.71% |
| CEO tenure | 13.4yrs |
| CEO ownership | 0.6% |
| Management average tenure | 4.9yrs |
| Board average tenure | 13.4yrs |
Recent management updates
Recent updates
Narrative Update • Jul 31
VCEL: Raised Guidance And Buyback Will Support Stronger Forward Repricing
Analysts have raised their fair value estimate for Vericel stock from $42.00 to $55.00, citing recent price target increases that follow reported MACI performance in Q2, as well as guidance they consider achievable for the second half of the year. Analyst Commentary Recent Street research on Vericel has focused on how current expectations for MACI and the broader MedTech backdrop feed into risk and reward for the stock.
Narrative Update • Jul 17
VCEL: Raised Outlook And New Headquarters Will Support Stronger Future Position
Vericel's implied fair value estimate has moved from about $53.88 to $57.14 as analysts adjust their price targets, citing updated expectations around revenue growth, profit margins and sector volatility. What’s in the News for Vericel Vericel approved an amendment to the company’s bylaws to reflect the relocation of its principal executive offices to a new global headquarters at 25 Blue Sky Drive, Burlington, Massachusetts 01803.
Narrative Update • Jun 26
VCEL: Strong Q1 Execution And BARDA Contract Will Drive Future Upside
Analysts have raised their fair value estimate for Vericel to $70.00 from $64.00, citing updated assumptions on revenue growth, profit margins, and future P/E, even as some Street targets such as Truist's have recently moved lower. What’s in the News for Vericel Analysts highlighted Vericel’s recent first quarter results, where revenues were reported at 7.6% above expectations and statutory losses were reduced, according to a summary of Wall Street research (source: Zacks / TD Cowen coverage summary).Analysis Article • Jun 22
Vericel (VCEL) Stock Could Be 37.3% Undervalued After Earnings Beat And Fund Buying
Vericel (VCEL) has drawn fresh attention after institutional holders such as BlackRock and State Street lifted their positions, and the company reported quarterly earnings per share that came in above market expectations. See our latest analysis for Vericel. Vericel's share price has picked up momentum recently, with a 1-day share price return of 2.48%, 7-day return of 7.05%, and 90-day return of 23.57%. This comes even though the 1-year total shareholder return declined 4.57% and the 5-year...Analysis Article • May 09
The Vericel Corporation (NASDAQ:VCEL) First-Quarter Results Are Out And Analysts Have Published New Forecasts
As you might know, Vericel Corporation ( NASDAQ:VCEL ) just kicked off its latest quarterly results with some very...New Narrative • May 02
Expanded Cell Therapy Capacity And Burn Care Franchise Will Drive Multiyear Upside Potential
Catalysts About Vericel Vericel develops and manufactures advanced cell therapies for cartilage repair and severe burn care. What are the underlying business or industry changes driving this perspective?New Narrative • Apr 17
Expanded Cell Therapy Pipeline Will Face Execution Risks Yet Ultimately Support Healthier Business
Catalysts About Vericel Vericel develops and manufactures advanced cell therapies for sports medicine and burn care, including MACI for cartilage repair and Epicel and NexoBrid in burn care. What are the underlying business or industry changes driving this perspective?Seeking Alpha • Jan 04
Vericel: Growth Plans May Have Run Out Of Gas (Rating Downgrade)
Summary Vericel (VCEL) is rated a hold due to inconsistent growth, fluctuating profitability, and limited near-term upside at current valuation. VCEL’s future hinges on scaling MACI, as Epicel and Nexobrid have stalled and face capped demand in niche markets. International expansion and MACI Arthro could drive growth, but execution risks and delayed timelines temper confidence in acceleration. Despite strong cash and no long-term debt, persistent SG&A growth and negative free cash flow highlight challenges in achieving sustainable profitability. Read the full article on Seeking AlphaAnalysis Article • Nov 12
There's No Escaping Vericel Corporation's (NASDAQ:VCEL) Muted Revenues Despite A 29% Share Price Rise
Vericel Corporation ( NASDAQ:VCEL ) shares have had a really impressive month, gaining 29% after a shaky period...Analysis Article • Jun 16
Does Vericel (NASDAQ:VCEL) Deserve A Spot On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Analysis Article • May 01
Risks To Shareholder Returns Are Elevated At These Prices For Vericel Corporation (NASDAQ:VCEL)
With a median price-to-sales (or "P/S") ratio of close to 9.6x in the Biotechs industry in the United States, you could...Seeking Alpha • Mar 06
Vericel: Scalable Growth With Strong Margins
Summary Vericel's niche in regenerative medicine is undervalued, with FDA-approved products like MACI, Epicel, and NexoBrid driving steady revenue growth and profitability. The company's strong financials include $167 million in cash, zero debt, and a 16% year-over-year revenue increase, highlighting operational efficiency. MACI's expansion into ankle cartilage repair and a robust pipeline suggest significant future earnings potential, despite current market hesitations. VCEL's strategy focuses on indication expansion and market penetration, aiming for long-term margin growth and reduced vulnerability to high-risk drug development. Read the full article on Seeking AlphaSeeking Alpha • Dec 19
Vericel Corporation: Hard To Justify Current Valuation
Summary Vericel Corporation, specializing in cellular therapies for sports medicine and severe burn care, has seen a 40% rise in its stock recently. Core products include MACI, NexoBrid, and Epicel, with Q3 revenues rising 27% year-over-year to $57.9 million, beating expectations. The company is turning the corner on profitability, but valuations look stretched at current trading levels. An analysis around Vericel follows in the paragraphs below. Read the full article on Seeking AlphaAnalysis Article • Nov 09
Vericel Corporation (NASDAQ:VCEL) Stock Rockets 32% As Investors Are Less Pessimistic Than Expected
Vericel Corporation ( NASDAQ:VCEL ) shares have had a really impressive month, gaining 32% after a shaky period...
New Narrative • Sep 10
MACI And NexoBrid Drive Record Revenues And Profit Growth, Setting Stage For Robust Future Performance
Expansion of MACI and NexoBrid markets driving record revenues, indicating significant future revenue growth.Analysis Article • Jul 12
What Vericel Corporation's (NASDAQ:VCEL) P/S Is Not Telling You
With a median price-to-sales (or "P/S") ratio of close to 11.3x in the Biotechs industry in the United States, you...Analysis Article • May 11
Vericel Corporation (NASDAQ:VCEL) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
Vericel Corporation ( NASDAQ:VCEL ) just released its first-quarter report and things are looking bullish. Revenues and...Analysis Article • Apr 26
It's Unlikely That The CEO Of Vericel Corporation (NASDAQ:VCEL) Will See A Huge Pay Rise This Year
Key Insights Vericel will host its Annual General Meeting on 1st of May Salary of US$790.0k is part of CEO Nick...Analysis Article • Mar 02
Is There An Opportunity With Vericel Corporation's (NASDAQ:VCEL) 49% Undervaluation?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Vericel fair value estimate is US$87.12 Vericel is estimated...Analysis Article • Feb 02
Revenues Not Telling The Story For Vericel Corporation (NASDAQ:VCEL) After Shares Rise 29%
Vericel Corporation ( NASDAQ:VCEL ) shareholders would be excited to see that the share price has had a great month...Analysis Article • May 05
Vericel Corporation's (NASDAQ:VCEL) Shareholders Might Be Looking For Exit
It's not a stretch to say that Vericel Corporation's ( NASDAQ:VCEL ) price-to-sales (or "P/S") ratio of 9.4x right now...CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | US$24m |
| Mar 31 2026 | n/a | n/a | US$21m |
| Dec 31 2025 | US$11m | US$860k | US$17m |
| Sep 30 2025 | n/a | n/a | US$13m |
| Jun 30 2025 | n/a | n/a | US$7m |
| Mar 31 2025 | n/a | n/a | US$3m |
| Dec 31 2024 | US$10m | US$830k | US$10m |
| Sep 30 2024 | n/a | n/a | US$4m |
| Jun 30 2024 | n/a | n/a | US$789k |
| Mar 31 2024 | n/a | n/a | US$451k |
| Dec 31 2023 | US$7m | US$790k | -US$3m |
| Sep 30 2023 | n/a | n/a | -US$10m |
| Jun 30 2023 | n/a | n/a | -US$13m |
| Mar 31 2023 | n/a | n/a | -US$17m |
| Dec 31 2022 | US$9m | US$760k | -US$17m |
| Sep 30 2022 | n/a | n/a | -US$18m |
| Jun 30 2022 | n/a | n/a | -US$16m |
| Mar 31 2022 | n/a | n/a | -US$11m |
| Dec 31 2021 | US$13m | US$730k | -US$7m |
| Sep 30 2021 | n/a | n/a | US$214k |
| Jun 30 2021 | n/a | n/a | US$9m |
| Mar 31 2021 | n/a | n/a | US$4m |
| Dec 31 2020 | US$4m | US$675k | US$3m |
| Sep 30 2020 | n/a | n/a | US$145k |
| Jun 30 2020 | n/a | n/a | -US$3k |
| Mar 31 2020 | n/a | n/a | -US$12m |
| Dec 31 2019 | US$5m | US$634k | -US$10m |
Compensation vs Market: Nick's total compensation ($USD11.16M) is above average for companies of similar size in the US market ($USD5.17M).
Compensation vs Earnings: Nick's compensation has been consistent with company performance over the past year.
CEO
Nick Colangelo (62 yo)
13.4yrs
Tenure
US$11,156,368
Compensation
Mr. Dominick C. Colangelo, also known as Nick, Esq., has been the Chief Executive Officer and President at Vericel Corporation since March 1, 2013 and served as its Treasurer since May 7, 2014. He has been...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 13.4yrs | US$11.16m | 0.61% $ 13.9m | |
| CFO & Treasurer | 5.6yrs | US$3.24m | 0.031% $ 713.0k | |
| Chief Operating Officer | 7.2yrs | US$3.62m | 0.032% $ 730.3k | |
| Chief Legal Officer | 6.8yrs | US$2.55m | 0.0032% $ 73.4k | |
| Chief Medical Officer | 8yrs | US$2.56m | 0.15% $ 3.4m | |
| Principal Accounting Officer | 4.5yrs | no data | 0.0021% $ 48.1k | |
| Vice President of Finance & Investor Relations | no data | no data | no data | |
| Chief Marketing Officer | 1.6yrs | no data | no data | |
| Senior Vice President of Corporate Development & Strategy | 4.9yrs | no data | no data | |
| Senior Vice President of Sales | 2.6yrs | no data | no data | |
| Chief Human Resources Officer | 2.1yrs | US$3.21m | 0.0036% $ 82.6k | |
| Senior Vice President of Operations | 4.5yrs | no data | no data |
4.9yrs
Average Tenure
57.5yo
Average Age
Experienced Management: VCEL's management team is considered experienced (4.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 13.4yrs | US$11.16m | 0.61% $ 13.9m | |
| Independent Director | 11.6yrs | US$357.80k | 0.036% $ 815.1k | |
| Independent Director | 11.6yrs | US$348.43k | 0.037% $ 837.5k | |
| Independent Chairman & Lead Director | 20.6yrs | US$395.30k | 0.064% $ 1.5m | |
| Independent Director | 20.9yrs | US$365.30k | 0.13% $ 2.9m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 16.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 16.3yrs | no data | no data | |
| Independent Director | 13yrs | US$355.30k | 0.068% $ 1.6m | |
| Independent Director | 5.2yrs | US$342.80k | 0.031% $ 705.9k |
13.4yrs
Average Tenure
65.5yo
Average Age
Experienced Board: VCEL's board of directors are seasoned and experienced ( 13.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/14 23:03 |
| End of Day Share Price | 2026/08/14 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vericel Corporation is covered by 20 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Keay Nakae | Ascendiant Capital Markets LLC |
| Michael Gorman | BTIG |
| Caitlin Cronin | Canaccord Genuity |